Article
Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention.
Clinical pharmacokinetics - 1 Jul 2018
Lei He-Ping, Yu Xi-Yong, Wu Hong, Kang Yan-Hong, Zhong Wan-Ping, Cai Li-Yun, Zhang Meng-Zhen, Chen Ji-Yan, Mai Li-Ping, Ding Qing-Shan, Yang Min, Zhong Shi-Long
Abstract excerpt
INTRODUCTION AND OBJECTIVE: The relationship between either paraoxonase 1 (PON1) gene promoter DNA methylation or genetic variations and bleeding or major adverse cardiac events after dual antiplatelet therapy has been incompletely characterized. We aimed to systematically investigate the role of genetic variations and DNA methylation of the PON1 CpG island promoter on the clinical outcomes of dual antiplatelet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.